These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 2491983)

  • 1. Removal of viral contaminants by monoclonal antibody purification of plasma proteins.
    Schreiber AB; Hrinda ME; Newman J; Tarr GC; D'Alisa R; Curry WM
    Curr Stud Hematol Blood Transfus; 1989; (56):146-53. PubMed ID: 2491983
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Affinity chromatography to remove viruses during preparation of plasma derivatives.
    Lawrence JE
    Dev Biol Stand; 1993; 81():191-7. PubMed ID: 8174803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pasteurized, monoclonal antibody factor VIII concentrate: establishing a new standard for purity and viral safety of plasma-derived concentrates.
    Goldsmith JC
    Blood Coagul Fibrinolysis; 2000 Mar; 11(2):203-15. PubMed ID: 10759015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunoaffinity purification of factor VIII.
    Weinstein RE
    Ann Clin Lab Sci; 1989; 19(2):84-91. PubMed ID: 2502062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of hemophilia A with a highly purified factor VIII concentrate prepared by anti-FVIIIc immunoaffinity chromatography.
    Addiego JE; Gomperts E; Liu SL; Bailey P; Courter SG; Lee ML; Neslund GG; Kingdon HS; Griffith MJ
    Thromb Haemost; 1992 Jan; 67(1):19-27. PubMed ID: 1615478
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Large-scale production and properties of human plasma-derived activated Factor VII concentrate.
    Tomokiyo K; Yano H; Imamura M; Nakano Y; Nakagaki T; Ogata Y; Terano T; Miyamoto S; Funatsu A
    Vox Sang; 2003 Jan; 84(1):54-64. PubMed ID: 12542734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Evaluation of viral safety of a high-purity human factor VIII concentrate submitted to 2 specific virus inactivation treatments (FANDHI)].
    Ristol P; Gensana M; Fernández J; Massot M; Biescas H; Darling A; Jorquera JI; Vericat F
    Sangre (Barc); 1996 Apr; 41(2):131-6. PubMed ID: 9045353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Initial clinical experience with a new pasteurized monoclonal antibody purified factor VIIIC.
    Smith KJ; Lusher JM; Cohen AR; Salzman P
    Semin Hematol; 1990 Apr; 27(2 Suppl 2):25-9. PubMed ID: 2128855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved safety from plasma derivatives: purification and viral elimination characteristics of mononine.
    Feldman F; Chandra S; Huang C
    Acta Haematol; 1995; 94 Suppl 1():25-32; discussion 33-4. PubMed ID: 7571992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ultracentrifugal analysis of factor VIII and von Willebrand factor in therapeutic preparations.
    Aronson DL; Chang P
    Vox Sang; 1995; 69(1):8-13. PubMed ID: 7483501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical characterization of a new pasteurized monoclonal antibody purified factor VIIIC.
    Hrinda ME; Feldman F; Schreiber AB
    Semin Hematol; 1990 Apr; 27(2 Suppl 2):19-24. PubMed ID: 2128854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inactivation of HIV-1 and HIV-2 by various manufacturing procedures for human plasma proteins.
    Hilfenhaus JW; Gregersen JP; Mehdi S; Volk R
    Cancer Detect Prev; 1990; 14(3):369-75. PubMed ID: 2117485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunoaffinity purification of factor VIII complex.
    Hornsey VS; Griffin BD; Pepper DS; Micklem LR; Prowse CV
    Thromb Haemost; 1987 Feb; 57(1):102-5. PubMed ID: 3109055
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Manufacturing process of anti-thrombin III concentrate: viral safety validation studies and effect of column re-use on viral clearance.
    Morrica A; Nardini C; Falbo A; Bailey AC; Bucci E
    Biologicals; 2003 Sep; 31(3):165-73. PubMed ID: 12935804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Viral safety and inhibitor development associated with factor VIIIC ultra-purified from plasma in hemophiliacs previously unexposed to factor VIIIC concentrates. The Monoclate Study Group.
    Lusher JM; Salzman PM
    Semin Hematol; 1990 Apr; 27(2 Suppl 2):1-7. PubMed ID: 1965615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Removal and inactivation of hepatitis B virus from contaminated pooled plasma in a large-scale manufacturing process for factor VIII and human serum albumin.
    Murozuka T; Aoki M; Kimura N; Sotoyama K; Abe I; Izumi H; Emura H; Takeda Y; Nanakawa H; Katsubayashi Y; Takeuchi T; Ito H; Hirakawa S; Mitsunaga S; Tadokoro K; Kanemitsu K; Miyamoto M; Yamanaka R; Nishioka K
    Vox Sang; 1999; 76(3):181-6. PubMed ID: 10341335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chromatographic removal of viruses from plasma derivatives.
    Burnouf T
    Dev Biol Stand; 1993; 81():199-209. PubMed ID: 8174804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human anti-mouse immunoglobulins in sera of patients treated chronically with monoclonal antibody-purified factor VIII.
    Haimovich J; Davis HM; Schreiber AB
    Semin Hematol; 1990 Apr; 27(2 Suppl 2):11-5. PubMed ID: 2128852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Specific inactivation of viruses which can potentially contaminate blood products.
    Horowitz B
    Dev Biol Stand; 1991; 75():43-52. PubMed ID: 1794631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Removal of parvovirus B19 from contaminated factor VIII during fractionation.
    Schwarz TF; Roggendorf M; Hottenträger B; Stolz W; Schwinn H
    J Med Virol; 1991 Sep; 35(1):28-31. PubMed ID: 1940880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.